Cell suspension for use in the treatment of lower extremity peripheral artery disease

A cell suspension comprising from 4×108 to 1.2×109 white blood cells derived from the bone marrow of a human subject, wherein of the total number of from 4×108 to 1.2×109 white blood cells:

• i. 20% to 51% are lymphocytes, and 3.9% to 22.3% are monocytes;
• ii. 1.4% to 10% are hematopoietic stem cells that express CD34;
• iii. 25.3% to 83.3% of the total number of white blood cells are mononuclear cells;
• iv. 16.7% to 74.7% of the total number of white blood cells are granulocytes;
• v. 5.4% to 38.8% of the total number of white blood cells express CXCR4;
• vi. 0.07% to 24.7% of total number of white blood cells express VEGFR2;
• vii. of the total number of hematopoietic stem cells that express CD34, 7.7% to 55.5% are early, non-committed hematopoietic stem cells that do not express CD38 and 0.7% to 10.3% are stem cells that express CXCR4;
• and
• viii. the maximum ratio of red blood cells to leucocyte cells is 6.7 and the maximum ratio of platelets to leucocyte cells is 32;
• wherein the cell suspension is for use in the treatment or amelioration of lower extremity peripheral artery disease;
• and wherein the cell suspension is derived from the same subject that is intended to receive the cell suspension or is derived from a different subject that is intended to receive the cell suspension.